Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II first-line capecitabine + bevacizumab study in metastatic colorectal cancer
2005-001919-21Phase 2Completed
- Sponsor
- Martin Luther University Halle-Wittenberg Medical Faculty
- Start
- Jul 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and bevacizumab in colorectal cancer (CRC), sponsored by Martin Luther University Halle-Wittenberg Medical Faculty. Primary endpoints: Progression-free survival rate at 9 months and Tolerability and feasibility. Started Jul 2006; status: completed.
02
Drugs
capecitabinebevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2005-001919-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001919-21.